Leveraging CRISPR to target and rapidly destroy glioblastoma cells


The gene-editing technology CRISPR shows early promise as a therapeutic strategy for the aggressive and difficult-to-treat brain cancer known as primary glioblastoma, according to findings of a new study.

Using a novel technique they’ve dubbed “cancer shredding,” the researchers programmed CRISPR to zero-in on repeating DNA sequences present only in recurrent tumor cells—and then obliterate those cells by snipping away at them. Working with cell lines from a patient whose glioblastoma returned after prior treatments, the team used CRISPR to destroy the tumor cells while sparing healthy cells.

“Glioblastoma is the most common lethal brain cancer, and patients still don’t have any good treatment options,” says the lead author of the study. “Patients typically receive chemotherapy, radiation, and surgery, but most relapse in matter of months. We wanted to find out if we could do something outside the box that could get around this problem of recurrence.”   

Cancer treatments rarely kill all tumor cells. In glioblastoma, as with many other highly recurrent cancers, tumor cells that escape treatment develop multiple genetic adaptations, or mutations, that allow them to proliferate. Building from their earlier research, the team surmised that these mutated cells have a unique genetic signature that could be targeted.

Using computational methods to analyze whole genomes of cancer cells, the team dove deep into the non-coding DNA to identify repetitive code all of them shared, even if they harbored a different variety of mutations. Then, armed with that data, they were able to guide CRISPR to the mutated cancerous cells and destroy them.

“We see CRISPR as a gateway to a new therapeutic approach that won’t be subject to the possibility of tumor cell escape,” the author says. “Cancer shredding could hold potential not only for glioblastoma, but possibly for other hypermutated tumors.” 

Until very recently, CRISPR has been used mainly in the development of therapies or as a valued research tool, but not as a treatment modality in itself. That changed in mid-November when UK regulators approved the first CRISPR-based therapy, which is designed to cure sickle cell disease and beta thalassemia. In the US, the FDA is expected to issue a decision on the same therapeutic approach in early December. 

The team behind the new study say much work is needed to advance their promising findings into a therapy that’s ready to be tested in patients. Among the remaining challenges are determining how CRISPR should be delivered to patients with glioblastoma, and how to ensure no unintended off-target effects.

https://www.cell.com/cell-reports/fulltext/S2211-1247(23)01351-7

http://sciencemission.com/site/index.php?page=news&type=view&id=publications%2Ftargeting-the-non&filter=22

Rating

Unrated
Rating: